News
Daily Aspirin Reduced Recurrent Venous Thromboembolism
- Author:
- Jane Salodof MacNeil
Publish date: May 23, 2012
News
Lenalidomide Maintenance Stalls Myeloma in Trio of Clinical Trials
- Author:
- Jane Salodof MacNeil
Publish date: May 9, 2012
News
Breast Brachytherapy Doubles Mastectomy Risk
- Author:
- Jane Salodof MacNeil
Publish date: May 1, 2012
News
Radiotherapy Comparison Favors IMRT for Prostate Cancer
- Author:
- Jane Salodof MacNeil
Publish date: April 17, 2012
Major Finding: Men who received IMRT were about 20% less likely to receive additional cancer therapy with an absolute risk of 2.5 vs. 3.1 per 100...
News
Practice Changers Expected at San Antonio Breast Cancer Symposium
- Author:
- Jane Salodof MacNeil
Publish date: December 6, 2011
News
JAK Inhibitor Ruxolitinib Wins First FDA Approval in Myelofibrosis
- Author:
- Jane Salodof MacNeil
Publish date: November 17, 2011
News
FDA Approves Deferiprone for Transfusional Iron Overload
- Author:
- Jane Salodof MacNeil
Publish date: October 14, 2011
News
FDA Approves Vemurafenib for Advanced Melanoma
- Author:
- Jane Salodof MacNeil
Publish date: August 19, 2011
News
FDA Approves Vemurafenib for Advanced Melanoma
- Author:
- Jane Salodof MacNeil
Publish date: August 17, 2011
News
Q&A: Putting New Melanoma Drugs to Work in Community Practice
- Author:
- Jane Salodof MacNeil
Publish date: August 17, 2011
News
Q&A: Putting the New Melanoma Drugs to Work
- Author:
- Jane Salodof MacNeil
Publish date: August 17, 2011
News
BRAF Inhibitor Cuts Death Risk in Advanced Melanoma
- Author:
- Jane Salodof MacNeil
Publish date: June 5, 2011
Major Finding: Survival estimates at a median 3 months’ of follow-up suggest 84% of patients treated with vemurafenib would be alive at 6 months...
News
ASCO: BRAF Inhibitor Cuts Death Risk in Advanced Melanoma
- Author:
- Jane Salodof MacNeil
Publish date: June 5, 2011
Major Finding: Survival estimates at a median 3 months' of follow-up suggest 84% of patients treated with vemurafenib would be alive at 6 months...
News
BRAF Inhibitor Cuts Death Risk in Advanced Melanoma
- Author:
- Jane Salodof MacNeil
Publish date: June 5, 2011
Major Finding: Survival estimates at a median 3 months’ of follow-up suggest 84% of patients treated with vemurafenib would be alive at 6 months...
News
Exemestane Prevented Breast Cancers in Postmenopausal Women
- Author:
- Jane Salodof MacNeil
Publish date: June 5, 2011
Major Finding: The annual incidence of invasive breast cancer was 0.19% with exemestane vs. 0.55% with placebo (hazard ratio 0.35, P = .002).Data...